There is a growing interest for connections between the central nervous system (CNS) and systemic immune and/or inflammatory responses. The inflammatory cytokine IL-1 has a wide spectrum of targets, which include the CNS. Intracerebroventricular as well as systemic administration of IL-1 were reported to induce central effects including fever (1), slow-wave sleep (2), anorexia (3), and activation of the hypothalamus-pituitary axis leading to release of adrenal corticosteroids (4, 5). Moreover, different brain cells such as astrocytes, microglia, and neurons can respond and/or have been found to contain various cytokines like IL-1, IL-2, IL-6, and TNF, and there is evidence that these factors act on neuronal survival, growth, and differentiation (1, 3, 6-10).
Results and Discussion intracerebroventricularly, no IL-6 induction was observed (IL-6 levels were <50 U/ml), thus ruling out the possibility that endotoxin contamination of the rIL-1 preparation could be responsible for the observed effect .
The higher serum IL-6 levels observed when IL-1 was administered intracerebroventricularly rather than systemically clearly rule out the possibility that induction of 60 120 180 24o Time (min) FIGURE 1 . Effect of administration of IL-1 (200 ng/rat) by different routes on serum IL-6 levels . The effect of intracerebroventricular administration was compared with that of intravenous or intraperitoneal administration. In these experiments, IL-6 levels in rats injected intracerebroventricularly were significantly higher (p <0 .01 by student's t test) than those of rats where IL-1 was given intravenously or intraperitoneally. IL-6 levels in rats given an equal volume of saline (intraperitoneally, intravenously, or intracerebroventricularly) were below the detection limit (<50 U/ml) . Data represent mean ± SD of four to five rats per group. circulating IL-6 by intracerebroventricularly administered IL-1 might be due to a passage of IL-1 into the circulation through the blood brain barrier.
The effect of IL-1 on hypothalamic thermoregulatory centers is known to be mediated by prostaglandins (1, 18) . It was therefore important to evaluate whether products of arachidonate metabolism were involved in induction of systemic IL-6 by intracerebroventricular IL-1 . We have studied the effect of pretreatment with an inhibitor of prostaglandin synthesis, indomethacin (20 mg/kg, i.p ., 1 h before IL-1), which was previously shown to inhibit the pyrogenic action of IL-1 administered intracerebroventricularly (19, 20) . The results reported in Fig. 3 show that indomethacin did not abolish the effect of centrally administered IL-1 on serum IL-6 levels . It should be noted that indomethacin alone increased serum IL-6 levels, although to a lesser extent than IL-1 . Maximal induction of IL-6 by indomethacin alone was at 2 h, and was also observed with 30 mg/kg of another cyclooxygenase inhibitor, ibuprofen (data not shown) . One possibility for the inducing effect of cyclooxygenase inhibitors on IL-6 levels is that prostaglandins provide an inhibitory signal for IL-6 synthesis, as it was reported for IL-1 (21) .
IL-1 activates the hypothalamus-pituitary axis, causing release of pituitary hormones and, ultimately, glucocorticoids (4, 5) . It was therefore important to ascertain whether the activation of the hypothalamus-pituitary axis is responsible for the induction of serum IL-6 by centrally administered IL-1 . For this purpose, we have studied the induction of IL-6 in hypophysectomized rats. As shown in Fig. 4 A, hypophysectomy did not block the induction of IL-6 by centrally administered IL-1 . Indeed, in all the experiments, hypophysectomy increased the IL-6 response .
We have also considered the possibility that IL-6 could be released by the adrenals, which were reported to contain high levels of IL-1 that could be released by degranulation of catecholaminergic terminals (22) . Results obtained using adrenalectomized rats are shown in Fig. 4 B. Adrenalectomy also increased the induction of IL-6 by centrally administered IL-1 . It should be pointed out that adrenalectomy, like hypophysectomy, increased IL-6 levels even after intraperitoneally administered IL-1 (data not shown), confirming our previous reports of a higher sensitivity of adrenalectomized animals to IL-1, probably due to the absence of feedback mechanisms mediated by corticosteroids (23) .
Taken together, these data rule out the possibility that induction of serum IL-6 by centrally administered IL-1 is secondary to its pyrogenic action mediated by prostaglandins or to the stimulation of the hypothalamus-pituitary axis . The finding that intracerebroventricular administration of IL-1 induces circulating IL-6 levels extends the list of central activities of IL-1 and indicates the existence of a novel pathway that could explain how infections or lesions confined to the CNS result in systemic alterations of acute-phase response parameters . The role played by IL-1 under conditions involving disturbances in the neurotransmission has been up to now poorly investigated . Glia cells are known to synthesize and store IL-1, as well as other cytokines (6) (7) (8) (9) (10) , and reactive gliosis with elevated IL-1 activity has been recently reported after brain injury and in neuropathological diseases like Down's syndrome and Alzheimer's disease (24, 25) . It was also shown that elevated levels of IL-6 are present in the cerebrospinal fluid of patients with meningitis (26) , and both IL-1 and IL-6 were found in cerebrospinal fluid of patients with HIV-1 infection of the CNS (27) .
The origin of the high blood levels of IL-6 induced by intracerebroventricular IL-1 remains to be established . IL-6 could be produced in the brain, for instance, by microglial cells (8, 10) or endothelial cells in the plexus chorioideus; alternatively, via an yet undefined pathway, production could be induced at peripheral sites.
The mechanism by which IL-1 can stimulate IL-6 production by a CNS-mediated pathway is still unclear. Studies are in progress to investigate the brain areas and the neurotransmitters implicated in this effect of IL-1 on the CNS and the source of the IL-6 released . Whatever the cellular origin and pathways involved, the observations reported herein provide a link whereby IL-1 produced intracerebrally or reaching the CNS can elicit a systemic acute-phase response. Received for publication 23 January 1990.
